• No se han encontrado resultados

Insertion of Drug Delivery Implants

N/A
N/A
Protected

Academic year: 2023

Share "Insertion of Drug Delivery Implants "

Copied!
3
0
0

Texto completo

(1)

Clinical Coverage Guideline page 1

Original Effective Date: 1/9/2014 - Revised: 7/10/2014, 6/5/2015

INSERTION OF DRUG DELIVERY IMPLANTS HS-236

Insertion of Drug Delivery Implants

Policy Number: HS-236

Original Effective Date: 1/9/2014 Revised Date(s): 7/10/2014; 6/5/2015

Easy Choice Health Plan, Inc.

Harmony Health Plan of Illinois, Inc.

Missouri Care, Inc.

‘Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc.

WellCare Health Insurance of Illinois, Inc.

WellCare Health Plans of New Jersey, Inc.

WellCare Health Insurance of Arizona, Inc.

WellCare of Florida, Inc.

WellCare of Connecticut, Inc.

WellCare of Georgia, Inc.

WellCare of Kentucky, Inc.

WellCare of Louisiana, Inc.

WellCare of New York, Inc.

WellCare of South Carolina, Inc.

WellCare of Texas, Inc.

WellCare Prescription Insurance, Inc.

Windsor Health Plan

Windsor Rx Medicare Prescription Drug Plan

APPLICATION STATEMENT

The application of the Clinical Coverage Guideline is subject to the benefit determinations set forth by the Centers for Medicare and Medicaid Services (CMS) National and Local Coverage Determinations and state-specific Medicaid mandates, if any.

(2)

INSERTION OF DRUG DELIVERY IMPLANTS HS-236

Clinical Coverage Guideline page 2

Original Effective Date: 1/9/2014 - Revised: 7/10/2014, 6/5/2015

DISCLAIMER

The Clinical Coverage Guideline is intended to supplement certain standard WellCare benefit plans. The terms of a member’s particular Benefit Plan, Evidence of Coverage, Certificate of Coverage, etc., may differ significantly from this Coverage Position. For example, a member’s benefit plan may contain specific exclusions related to the topic addressed in this Clinical Coverage Guideline. When a conflict exists between the two documents, the Member’s Benefit Plan always supersedes the information contained in the Clinical Coverage Guideline. Additionally, Clinical Coverage Guidelines relate exclusively to the administration of health benefit plans and are NOT recommendations for treatment, nor should they be used as treatment guidelines. The application of the Clinical Coverage Guideline is subject to the benefit determinations set forth by the Centers for Medicare and Medicaid Services (CMS) National and Local Coverage Determinations and state-specific Medicaid mandates, if any. Note: The lines of business (LOB) are subject to change without notice; consult www.wellcare.com/Providers/CCGs for list of current LOBs.

BACKGROUND

Drug implant devices deliver active pharmaceuticals to a specific area in a member’s body for a determined length of time. Delivery of medication in this manner allows a member to receive a controlled release of a particular medication. Providers must replace and/or remove the implants at some point in time as they will not be absorbed by the body. Most implanted non-biodegradable delivery devices consist of an outer shell (e.g., silicon, ethylene vinyl acetate [EVA]) where the medication. Common medications include antibiotics, anti-inflammatories (steroids), and antivirals and may look like small beads, pellets, rods, slivers, or spacers.

POSITION STATEMENT

Applicable To:

Medicaid – All Markets Medicare – All Markets

The insertion of non-biodegradable drug delivery implant devices (CPT Code 11981) is considered medically necessary for the following:

Non-biodegradeable contraceptive subcutaneous devices; OR, Hormone implants; OR,

Treatment of advanced prostate cancer; OR,

Orthopedic wound re-opening with insertion of an antibiotic containing bone cement; OR,

Orthopedic wound re-opening with removal and reinsertion of an antibiotic containing bone cement; OR, Opthalmologic insertion of gancyclovir capsule via vitrectomy; OR,

Provider recommendation and member choice for contraception.

Indications not listed above are considered experimental / investigational and not a covered benefit.

CODING

Covered CPT®* Codes

11981 Insertion, Non-Biodegradable Drug Delivery Implant 11982 Removal, non-biodegradable drug delivery implant

11983 Removal with reinsertion, non-biodegradable drug delivery implant

Hormone Implants

ICD-9 Diagnosis Codes

256.2-256.39 Postablative and other ovarian failure 256.8 Other ovarian dysfunction

256.9 Unspecified ovarian dysfunction

627.0-627.9 Menopausal and postmenopausal disorders 780.79 Other malaise and fatigue

799.81 Decreased libido

(3)

INSERTION OF DRUG DELIVERY IMPLANTS HS-236

Clinical Coverage Guideline page 3

Original Effective Date: 1/9/2014 - Revised: 7/10/2014, 6/5/2015

ICD-10-CM Draft Codes

E28.310-E28.39 Primary ovarian failure E28.8 Other ovarian dysfunction E28.9 Ovarian dysfunction, unspecified E89.40-E89.41 Postprocedural ovarian failure

N95.0-N95.9 Menopausal and other perimenopausal disorders R53.81-R53.83 Other malaise and fatigue

R68.82 Decreased libido

Non-biodegradeable contraceptive subcutaneous devices:

Covered ICD-9-CM Diagnosis Codes

V25.11 Encounter for insertion of intrauterine contraceptive device V25.12 Encounter for removal of intrauterine contraceptive device

V25.13 Encounter for removal and reinsertion of intrauterine contraceptive device V25.5 Insertion of implantable subdermal contraceptive

Covered Draft ICD-10-CM Diagnosis Codes

Z30.430 Encounter for insertion of intrauterine contraceptive device Z30.432 Encounter for removal of intrauterine contraceptive device

Z30.433 Encounter for removal and reinsertion of intrauterine contraceptive device Z30.49 Encounter for surveillance of other contraceptives

Treatment of advanced prostate cancer

Covered ICD-9-CM Diagnosis Code

185 Malignant Neoplasm of Prostate Covered ICD-10-CM Diagnosis Code

C61 Malignant neoplasm of prostate

Treatment of orthopedic wound

Covered ICD-9 CM Diagnosis Code 730.10-730.19 Chronic osteomyelitits

Covered Draft 2014 ICD-10-CM Diagnosis Code

M86 Osteomyelitis

*Current Procedural Terminology (CPT®) 2015 American Medical Association: Chicago, IL.

REFERENCES

1. Health Coding Pro. (2012, February 22). Get the facts on coding for non-biodegradable drug delivery implants. Just Coding News:

Outpatient. Retrieved from http://www.hcpro.com/HIM-276779-8160/Get-the-facts-on-coding-for-nonbiodegradeable-drug-delivery- implants.html

MEDICAL POLICY COMMITTEE HISTORY AND REVISIONS

Date Action

6/5/2015 Approved by MPC. No changes.

7/10/2014 Approved by MPC. Inclusion of CPT 11892 and corresponding criteria.

1/9/2014 Approved by MPC.

Referencias

Documento similar

URINARY INCONTINENCE TREATMENT HS-080 Clinical Coverage Guideline page 10 90911 Biofeedback training, perineal muscles, anorectal or urethral sphincter, including EMG and/or

PEDIATRIC INSULIN PUMPS Kentucky HS-286 Covered ICD-10 CM Diagnosis Codes E08.00-E08.01 Diabetes mellitus due to underlying condition with hyperosmolarity with coma E08.01

EYE MOVEMENT DESENSITIZATION THERAPY FOR PTSD HS-071 Clinical Coverage Guideline page 4 Original Effective Date: 12/18/2008 - Revised: 12/22/2009, 12/28/2010, 1/5/2012, 12/6/2012,

VANTAS® HISTRELIN ACETATE IMPLANT FOR THE TREATMENT OF ADVANCED PROSTATE CANCER HS-101 Clinical Coverage Guideline page 3 Original Effective Date: 5/7/2009 - Revised: 5/28/2010,

Clinical Coverage Guideline page 6 ICD-9-CM Diagnosis Codes 174.0 Malignant neoplasm of female breast, nipple and areola 174.1 Malignant neoplasm of female breast, central portion

ARTIFICIAL DISC REPLACEMENT HS-046 Clinical Coverage Guideline page 4 Original Effective Date: 9/18/2008 - Revised: 9/18/2009, 9/24/2010, 9/1/2011, 9/6/2012, 9/5/2013, 9/4/2014,

MANAGING INFECTIONS HS-1037 Clinical Practice Guideline page 4 Original Effective Date: 12/8/2016 Revised: 10/10/2017  Understanding ways to control pain  Wearing footwear that